Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: luckydog88	7/25/2025 7:02:24 PM
	of 63281

REUTERS Jul-25-2025 5:50 p.m. ET July 25 (Reuters) - The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' (SRPT) muscular disorder gene therapy Elevidys. The death occurred on June 7, the agency said. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath) On a completely separate note, investment management company D.E. Shaw filed after hours tonight that they now own 5.1% of the shares outstanding. This is what institutional investor says about D.E. Shaw: As multistrategy hedge funds continued their hot streak last year, D.E. Shaw rose to the top of the 2024 rankings of the best performers by LCH Investments. D.E. Shaw made $11.1 billion for investors in 2024, the most of any of the top 20 managers in the ranking. Jan 19, 2025

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next